Compare Pfizer Inc (PFE) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Exxon Mobil Corporation — how do they compare? Pfizer Inc trades at $27.78 (market cap $159.59B), while Exxon Mobil Corporation trades at $166.65 (market cap $674.56B). The key difference: Exxon Mobil Corporation is far larger — about 4.2× Pfizer Inc's market cap, and Pfizer Inc pays the higher dividend (6.14%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Exxon Mobil Corporation for 99 Days on average.
| PFE | XOM | |
|---|---|---|
Market Cap | $159.59B | $674.56B |
Volume | 30,937,010 | 9,350,473 |
Sector | Health | Energy |
52-Week High | $29.02 | $171.52 |
52-Week Low | $23.67 | $110.64 |
Typical Hold Time | 158 Days | 99 Days |
Enterprise Value | $211.09B | $706.34B |
Dividend Yield | 6.14% | 2.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
ExxonMobil (XOM) trades at $168.56, up 2.48% with strong technical momentum and bullish moving average signals. The company maintains solid profitability with 9.07% net margin and 12.55% ROE, though revenue declined to $323.91B in 2025. Recent news highlights potential Venezuela investment and Guyana/Permian expansion, while analyst consensus shows 36% buy ratings with $168.08 price target.
XOM presents a balanced opportunity with operational strength and strategic growth initiatives, though faces headwinds from declining revenue trends and geopolitical risks. The stock's current valuation at 21.11 P/E appears reasonable given cash flow generation, but investors should monitor execution on production targets and oil price volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
